Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression - PubMed (original) (raw)

Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression

S F Tsang et al. J Virol. 1991 Dec.

Abstract

To delineate the cis-acting element through which EBNA-2 transactivates latent membrane protein 1 (LMP1), we assayed the effect of EBNA-2 on the activity of LMP1 promoter upstream deletion mutants in the context of the LMP1 or heterologous promoters controlling chloramphenicol acetyltransferase (CAT) reporter gene expression in Epstein-Barr virus-negative Burkitt lymphoma cells. Assays of progressive 5' deletions of the LMP1 promoter revealed low constitutive and at least eightfold EBNA-2-stimulated activity from -512 to +40 (-512/+40), -334/+40, and -234/+40 LMP1CAT plasmids. More extensive 5'-deleted -205/+40, -155/+40, and -147/+40 LMP1CAT plasmids also had low constitutive activity but were not EBNA-2 responsive. The most 5'-deleted -55/+40 LMP1CAT plasmid had moderate constitutive activity and was not EBNA-2 inducible. Either orientation of the -334/+40 LMP1 sequence conferred EBNA-2 responsiveness when positioned upstream of an enhancerless simian virus 40 or herpes simplex virus thymidine kinase (TK) promoter. EBNA-2 and the cis-acting LMP1 DNA were both required to increase TK promoter-initiated mRNA, indicating that the EBNA-2 effect is at the transcriptional level. Further deletion analysis of the EBNA-2-responsive cis-acting element defined a -234/-92 LMP1 DNA fragment which conveyed EBNA-2 responsiveness to the herpes simplex virus TK promoter. The 5' 30 bp between -234 and -205 were essential for EBNA-2 responsiveness. Thus, these experiments define a 142-bp cis-acting element which is sufficient for conveying EBNA-2 responsiveness and an essential 30-bp component of that element. The role of this element in LMP1 and LMP2B expression and its possible role in LMP2A expression are discussed.

PubMed Disclaimer

References

    1. J Virol. 1989 Apr;63(4):1531-9 - PubMed
    1. Biomedicine. 1975 Jul;22(4):276-84 - PubMed
    1. Methods Enzymol. 1987;152:704-20 - PubMed
    1. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9558-62 - PubMed
    1. Proc Natl Acad Sci U S A. 1987 May;84(10):3452-6 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources